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Abstract 
Pythium insidiosum is an aquatic oomycete that causes invasive, progressive granulomatous 
lesions of the skin in dogs, horses, and cats, and of the gastrointestinal tract in dogs.  Quantitation of 
anti-P. insidiosum IgG antibodies can be used in dogs to both confirm a suspected diagnosis and to 
monitor response to therapy.  Recently, an immunotherapeutic product (IP) has been marketed for the 
treatment of pythiosis in dogs, horses, and people.  The aim of this study was to evaluate the effect of 
administration of this product on anti-P. insidiosum IgG concentrations in dogs.  The IP was administered 
to seven, healthy hound mixes on days zero, seven and 21.  Serum was collected on days zero, seven, 
14, 21, 28, 35, 42, 49, and 56.  Anti-P. insidiosum antibody concentrations were measured using a 
previously-described ELISA that utilizes a soluble mycelial-based antigen, with results reported as 
percent positivity (PP) in comparison to a strong positive control serum.  Prior to immunotherapy 
administration, average PP was 7.45% +/- 3.02%.  Following immunotherapy administration, there was 
no significant change in anti-P. insidiosum antibody concentrations, with PP values in all dogs remaining 
within the range expected for healthy dogs (3% - 15%) for the entire study period.  In conclusion, the IP 
did not produce a significant change in anti-P. insidiosum IgG concentrations when administered to 
healthy dogs using the protocol suggested by the manufacturers.  Further investigation will be required 
to determine whether a similar effect is observed in naturally infected dogs.   
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Chapter 1. Introduction and Literature Review 
1.1 Pythium insidiosum 
1.1.A Brief history 
Pythium insidiosum is an aquatic oomycete of the kingdom Stramenopila, Class oomycetes, Order 
Pythiales and Family Pythiaceae [1].  It was historically called “bausette”, from “bausett”, the rainy 
season, by Veterinary Surgeon James Kerr in India in 1829; as a condition affecting horses “which 
appeared at the commencement of the rainy season and terminated as the dry season set in” [2].  The 
first cases were described as small tumors around the lips, face and scrotum [2].  If not treated, the 
tumors would “suppurate and become a bausette ulcer and from exposure to air become schirrous” [2].  
It was thought that the smallest abrasion in susceptible horses was enough for the development and 
these would “rapidly degenerate into bausette, if exposed to air” [2].  At this time, the etiology for this 
condition was unknown.  It wasn’t until 1879 in the East Indies that Smith reported that “bursattee” 
originated in the subcutaneous tissue, referred to the tumors as “kunkur stones”, and suggested the 
disease was caused by a mold-fungus [3].  In the United States in 1895, Dr. Pierre Fish wrote a historical 
account comparing “bursattee” of the East Indies and “leeches”, a similar disease of horses and cattle in 
Florida, as identical in nature [2].   
Around the early 1900’s, de Haan and Hoogkamer described several cases of diseased horses in 
Indonesia and named the disease as “hyphomycosis destruens” [4, 5].  In 1961, Bridges and Emmons 
then described the etiologic agent as Hyphomyces destruens, a phycomycete (zygomycete) on the basis 
of its morphology in equine tissue as well as its broad, branched sparsely septate to coenocytic, non-
sporulating mycelium in cultures [6].  At this time, the agent was unable to sporulate in the media used 
[6].  In 1974, Austwick and Copland reported the formation of biflagellate zoospores in isolates from 
horses with “swamp cancer” from Papua, New Guinea [7].  These were grown on Sabouraud dextrose 
agar and then transferred to an aqueous medium of rotten maize silage.  From these results, they 
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concluded that H. destruens was a phycomycete belonging to the Pythiaceae in the Peronosporales and 
could be included in the genus Pythium Pringsheim [7].   
It wasn’t until 1980 that Chandler, Kaplan and Ajello proposed changing the to the more appropriate 
term “pythiosis” (also called: bursatii, Florida leeches, granular dermatitis, hyphomycosis destruens 
equi, phycomycosis, phycomycotic granuloma and swamp cancer) [8].  In 1980, Ichitani and Amemiya 
isolated a Pythium sp. from a Japanese case of equine pythiosis [9].  Based on the filamentous 
zoosporangia, smooth oogonia, and aplerotic (oospores not filling the oogonium), smooth oospores that 
it produced, it was considered part of the pre-existing species called Pythium gracile Schenk [9].  During 
a two-year study of pythiosis in Costa Rican horses, numerous isolates of a Pythium species were studied 
at the Centers for Disease and Control in Atlanta, Georgia [10].  A reliable and sensitive immunodiffusion 
test for diagnosing pythiosis was then developed by Mendoza, Kaufman, and Standard [11].  Using the 
immunodiffusion and fluorescent-antibody tests, Mendoza et al. demonstrated that isolates from the 
horses in Costa Rica; Papua, New Guinea; United States; and Japan; isolates from humans in Thailand; 
and isolates from dogs in the United States were identical [11].  Additional morphologic studies 
demonstrated the formation of zoosporangia in water, which led the researchers to conclude that this 
was a new species of Pythium [10].  De Cock, Mendoza, Padhye, Ajello and Kaufman finally described the 
etiologic agent for pythiosis as Pythium insidiosum [10].   
1.1.B Organism 
The organism’s cell walls lack chitin and ergosterol but contain cellulose and β-glucan.  In this 
manner, P. insidiosum is more closely related to algae than it is to fungi [1].  P. insidiosum incorporates 
sterols from the environment rather than producing them itself [1].  The sexual reproductive structures 
are oogonia and antheridia, and the asexual reproductive structures are zoospores [10].  It undergoes 
asexual reproduction, which is characterized by the production of “motile, reniform, biflagellate 
zoospores that develop by progressive cleavage within a vesicle that forms at the end of a discharge 
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tube produced by a zoosporangium” [10].  Its sexual reproductive structures are “characterized by 
intercalary, smooth, and subglobose oogonia; diclinous antheridia that produce a rigid fertilization tube 
from their tip; and oospores that are aplerotic and often pressed to one side of the oogonium” [10].   
Due to the difficulties associated with induction of sporulation under laboratory conditions, the 
organism has been classified as a zygomycete or “phycomycete” [1].  P. insidiosum grows well at 37°C 
and produces motile biflagellate zoospores in water culture [1].  Since P. insidiosum isolates rarely 
produce sexual reproductive structures in the lab, presence and description of the hyphae, which are 
broad (mean of 4 µm; range 2-7 µm), rarely septate, and occasionally branching at right angles [1] help 
the clinician with diagnosis.  
P. insidiosum is found in subtropical to tropical aquatic environments in Asia, Australia, and parts of 
Central and South America [12].  Most infections with P. insidiosum (pythiosis) in the United States are 
seen during the summer and fall along the Gulf of Mexico [12].  Areas with stagnant water (especially 
associated with flooding or hurricanes) are frequently associated with outbreaks of pythiosis.   
1.1.C Pathogenesis 
The infectious form of P. insidiosum is the motile biflagellate zoospore which usually infects by 
encysting in damaged skin or GI mucosa [1].  The zoospore has an anterior tinsel flagellum and a 
posterior whiplash flagellum [10].  These allow the zoospore to locate, move toward, and encyst on 
specific host tissues or other substrates [1].  Zoospores then use chemotaxis, electrotaxis, and auto-
aggregation (i.e., dense accumulations of zoospores attract others, thereby increasing inoculum for 
infection) [1].  Once the zoospores contact an open wound, they “form a germ tube that mechanically 
penetrates tissues” [13].  Once into the tissues, P. insidiosum’s hyphae produce exoantigens that trigger 
an immune response with eosinophils, mast cells and sometimes IgE [13].  It has been proposed that the 
constant production of this exoantigen causes the host’s immune response to develop a Th2 
immunologic polarization [13].  However, no work to support this assertion has been performed.  The 
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“overwhelming number of degranulated eosinophils (Splendore-Hoeppli phenomenon) and mast cells 
around the hyphae of P. insidiosum are primarily responsible for the extensive and rapid tissue damage 
encountered during pythiosis” [13].  Splendore-Hoeppli reaction is thought to be a localized 
immunological response to an antigen-antibody precipitate related to fungi, parasites, bacteria or inert 
materials [14].  The formation of the Splendore-Hoeppli reaction may inhibit phagocytosis and 
intracellular killing of the agent leading to persistence of infection [14].  This hypothesis is supported by 
the fact that viable hyphae of P. insidiosum have been found only inside the eosinophilic reaction or 
inside kunkers in equine infections, suggesting that P. insidiosum might use the Splendore-Hoeppli 
phenomenon and kunkers for survival [13].   
1.1.D Species affected and clinical syndromes 
Species commonly affected by P. insidiosum include dogs, humans and horses, although there have 
also been cases reported in other animals such as cattle, sheep, birds, as well as animals held in captivity 
[15].  Affected dogs and horses are generally immunocompetent and otherwise healthy overall [1, 13, 
15]. In contrast, affected humans often suffer from some preexisting systemic illness, such as β-
thalassemia [16].   
Healthy dogs with access to water in the tropical and subtropical regions are commonly affected 
with P. insidiosum [12].  Usually infections appear to occur through damage of the skin, where the 
organism gains access while the animal is in flooded areas or when swimming [12].  The incidence is 
highest in young, male, large breed dogs, and lesions are most commonly on the limbs, perineum, tail, 
and head [17].  Pythiosis typically takes one of two clinical forms in the dog: cutaneous and 
gastrointestinal [1, 13, 15].  Cutaneous and gastrointestinal pythiosis seldom occur in the same patient 
[1].   
Cutaneous lesions typically appear as non-healing wounds or invasive, progressively enlarging, 
pyogranulomatous masses that contain ulcerated nodules and draining tracts [17].  Regional 
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lymphadenopathy is often present and may reflect extension of infection rather than just reactive 
inflammation [1].   
Gastrointestinal pythiosis is characterized by severe transmural thickening of the stomach, small 
intestine, colon, rectum, or, rarely, the esophagus [18].  Mesenteric lymphadenopathy is common, and 
the gastric outflow area and ileocecal junction are the most frequently infected portions [1].  It is not 
uncommon to find two or more segmental lesions in the same patient [1].  Most commonly, the 
submucosa is affected with variable mucosal ulceration and occasional extension through the serosal 
surfaces, which can result in adhesion formation and peritonitis [1].  Treatment of gastrointestinal 
pythiosis is challenging, as no treatment modality is 100% effective for all cases presented, and the 
prognosis is poor to grave [19].  It is best treated with wide (i.e., 3 to 4 cm margins) surgical excision, 
followed by prolonged courses (> 4 months) of antifungal chemotherapy [19].  Reports of survival have 
been documented in one case treated with partial gastrectomy, as well as another dog treated medically 
with a combination of itraconazole, terbinafine, and mefenoxam [19].   
In horses, pythiosis can also be referred to as swamp cancer, leeches or summer sores [20].  The two 
most common presentations are cutaneous and subcutaneous, although gastrointestinal involvement 
has been described [20].  No predisposing factors (age, sex, and breed) have been described; however, 
immunocompetent horses exposed to warm, fresh water in swampy areas are at an increased risk of 
contracting the infection [20].  Transmission is through colonization of traumatic lesions by zoospore 
and/or hyphae of P. insidiosum [21] or by ingestion of P. insidiosum-contaminated water [22].  Lesions 
typically occur on the limbs and ventral abdomen and are often intensely pruritic.  Patients may 
demonstrate mild to marked lymphadenopathy [20].  Lesions may demonstrate gritty, often branching 
yellow concretions (kunkers).  Kunkers in horses are formed by degranulation of eosinophils over the 
invading hyphae of P. insidiosum [21].  In chronic infections (> 4 weeks), the infection may spread to the 
underlying bone and cause lameness [21].  The only place where the hyphae can be found in these 
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chronic infections is within the kunkers [20].  Though most cases of pythiosis in horses are cutaneous 
and subcutaneous, intestinal infections have also been reported [21, 22].  Intestinal infections consist of 
stenotic fibrous and disseminated gastrointestinal lesions [21].  Cases with intestinal pythiosis are 
associated with clinical signs of colic that can be associated with partial luminal obstruction [22]. 
The development of pythiosis in humans is rare in the United States, but is commonly seen in 
Southeast Asia.  There are 4 types of pythiosis in humans: vascular (59%), ocular (33%), 
cutaneous/subcutaneous (5%) and miscellaneous forms (3%) [23].  In contrast to horses and dogs (which 
are typically otherwise healthy), humans with pythiosis are often immunologically compromised [23].  
These patients suffer from diseases such as aplastic anemia, β-thalassemia, α-thalassemia, paroxsysmal 
nocturnal hemoglobinuria and Hemoglobin E disease, all caused by mutations in the HBB gene [16, 23, 
24].  Patients typically have histories of exposures to rice fields or access to flooded or swampy areas for 
swimming.  Clinical signs depend on the type of infection, but most vascular pythiosis patients present 
with chronic arterial insufficiency syndrome of the lower extremities, which varies from intermittent 
claudication to gangrenous ulceration [23].   
1.1.E Methods of diagnosis 
1.1.E.1 Histology and immunohistochemistry 
The diagnosis of infection with P. insidiosum can be challenging.  Histologic examination of 
biopsy material may demonstrate the presence of broad, irregularly branching hyphae.  Although 
hyphae are difficult to visualize with H&E-stained sections, they may appear as hyphal-shaped “clear 
spaces” surrounded by a narrow band of eosinophilic material [1].  Hyphae are visualized easily in 
sections stained with Gomori’s methenamine silver (GMS), but not with periodic acid-Schiff (PAS) [1].  
Unfortunately, histologic examination alone cannot reliably distinguish the hyphae associated with P. 
insidiosum from those of some species of true fungi (e.g., Basidiobolus) [25].   
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Immunohistochemical techniques based on polyclonal antibodies have been developed for P. 
insidiosum by Brown [26] and Newton [27] and had been used as confirmatory tests [1].  However, these 
tests have been found to be cross-reactive with other species such as Conidiobolus, Basiodiobolus and 
Lagenidium hyphae [1].  Therefore, specificity of this antibody for the immunohistochemical diagnosis of 
pythiosis is questionable [1].   
An additional factor complicating the diagnosis of gastrointestinal pythiosis is the depth of the 
infection.  In these cases, granulomatous inflammation is often centered on the submucosal and 
muscular layers rather than the mucosa and lamina propria [1].  For this reason, the diagnosis can be 
missed on endoscopic biopsies that fail to reach deeper tissues [1].  Pythiosis should be considered a 
differential diagnosis when endoscopic biopsies reveal eosinophilic or pyogranulomatous inflammation 
without identification of an etiologic agent [1].   
1.1.E.2 Culture 
Pythium may be cultured from tissue, but the organism is somewhat susceptible to temperature 
extremes and may be killed by prolonged refrigeration, making transport inconvenient [25].  In addition, 
the use of inappropriate media and technique during culture can also lead to false negative results [25].  
In addition to this, induction of sporulation, which can facilitate proper identification, can be difficult in a 
laboratory setting [25].  
1.1.E.3 PCR 
Although molecular diagnostics can identify P. insidiosum, these methods are not readily 
available to most practitioners in a clinical setting [25].  Nested polymerase chain reaction (PCR) based 
assays for identification of P. insidiosum can be applied to DNA extracted from cultured isolates or from 
appropriately preserved infected tissue samples [28].  When using these tissues, Grooters found that 
freezing samples at -70° C, or storing them at ambient temperature in 95% ethanol adequately 
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preserved DNA for subsequent amplification [1].  Due to the sensitivity of this assay, archival samples 
may be also tested [1].   
1.1.E.4 ELISA 
Perhaps the most practical method of diagnosis of P. insidiosum, especially for the dog, is by the 
demonstration of anti-P. insidiosum IgG antibodies using an enzyme-linked immunosorbent assay 
(ELISA) [25].  An ELISA utilizes an enzyme conjugated to an anti-canine IgG antibody [29].  This conjugate 
reacts with a colorless substrate to generate a colored reaction product, with the amount of color 
indicating quantity of the product [29].   
This method also has the advantage of permitting evaluation of the course of treatment in dogs, as 
antibody levels generally rise and fall in conjunction with the host’s pathogen burden [18, 30]. In 
general, concentrations increase with the progression or worsening of infection [19, 30].   
The IgG ELISA used in this study has been previously described and evaluated in dogs and has a 
100% specificity and sensitivity for pythiosis [25].  Results of the assay are expressed as percent 
positivity (PP) in comparison with a strong positive control sample, with values > 40% positivity having 
been shown to be 100% sensitive and specific for canine pythiosis and values in healthy dogs ranging 
from 3-15% [25].  
1.1.E.5 Other assays 
Agar gel immunodiffusion (AGID) detects precipitating antibodies in the serum of most equine 
and human patients with active pythiosis, but often is negative in affected dogs [1].  Western 
immunoblot analysis has been used successfully to demonstrate the ability of sera from Pythium-
infected horses and dogs to recognize antigens of P. insidiosum, and it has the added advantage of high 
specificity and sensitivity [1].  However, this immunoblot technique is time and labor intensive 
compared to other techniques (e.g., ELISA) for the detection of antibodies in the serum [1].   
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1.1.F Prognosis and treatment 
1.1.F.1 Traditional treatment 
Treatment of pythiosis is challenging and consists of a multi-modal approach by wide-margin 
surgical excision (when possible) and antifungal chemotherapy for prolonged periods of time [25, 30, 
31].  Although P. insidiosum resembles fungi in culture and in tissue, it is not a true fungus and contains 
neither ergosterol nor chitin in its cell walls [10].  As most antifungal drugs primarily target these 
molecules, medical management alone generally has limited efficacy against P. insidiosum.  In addition, 
infections with the organism are typically very locally invasive, and often extend microscopically far 
further than their clinical appearance would suggest.  For this reason, radical excision or amputation of 
the affected area is usually recommended.  Unfortunately, diagnosis of pythiosis is often delayed as the 
lesions typically seen with P. insidiosum infections may easily be mistaken for other conditions, such as 
acral lick granulomas in dogs or “proud flesh” in horses.  Thus, lesions may become very large and/or 
extensive by the time a definitive diagnosis is made. 
A dramatic decrease in IgG concentrations has been seen in dogs and cats following successful 
surgical resection [1].  In contrast, antibody levels remain high in animals that develop recurrence 
following surgical treatment [1].  In this case, it is recommended to continue medical therapy with re-
evaluation of the ELISA every 2-3 months [1].  Efficacy of treatment depends on location of the lesion 
(thoracic vs limb), type of infection (vascular, cutaneous, or visceral), chronicity of the infection and the 
individual patient’s immune response (immune-compromised or immune-competent).  It has been 
reported that long-term infections of more than 4 weeks have a worse prognosis than early detected 
and treated infections [32].    
1.1.F.2 Immunotherapeutic Product development as newer form of treatment 
Recently, an immunotherapeutic product (IP) has been developed and marketed for use in the 
treatment of pythiosis in horses, dogs and humans.  The first IP for P. insidiosum was designed for 
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horses.  This product used a whole cell, killed, sonicated hyphal preparation of P. insidiosum and was 
developed by Miller in the 1980’s [33].  A positive response was observed within seven to 14 days after 
the first injection.  However, swelling and sterile abscesses were frequently observed at the injection 
site [34].  A subsequent improved formulation was designed to have enhanced immunotherapeutic 
properties due to the addition of both secreted exoantigens as well as cytoplasmic antigens of P. 
insidiosum [13].  In studies conducted by Mendoza et al. the new IP formulation, containing an equal 
mixture of exoantigens plus cytoplasmic immunogens, has been reported to produce clinical cure of 72% 
of the 26 injected horses, including chronic cases [13].  These findings suggested that the addition of 
cytoplasmic antigens dramatically increased the IP’s curative properties [13].   
There have been several reports in which the IP has been administered to dogs.  While some of 
these cases appear to have been successfully treated, the efficacy in canines seems to be less than that 
reported in horses [12, 19].  The majority of these cases have received both traditional therapy (medical 
or surgical) and the IP.  Oldenhoff reported administration of the IP to a 4-year old German shepherd; 
however, new lesions formed despite the initiation of the IP.  Traditional medical management 
(itraconazole and terbinafine) was added but the patient was later lost to follow-up [18].  Pereira 
reported a 2.5-year old Beagle in which intestinal pythiosis caused luminal obstruction, requiring 
exploratory laparotomy and biopsy.  After surgery, the beagle was administered the IP in addition to 
terbinafine and itraconazole.  The remaining affected area was completely resolved by 60 days [15].  
Hensel reported a 4-year old Labrador retriever with a lesion on the carpus.  After partial surgical 
excision, the retriever was administered the IP twice.  The lesion had resolved by one year post 
treatment [17].  Dykstra published a report of 2 dogs which were treated using a combination of 
immunotherapy and medical management [35].  Neither animal responded to treatment and both were 
euthanized shortly after presentation.  Schmiedt reported a 1.5-year mixed-breed dog with 1-month 
history of vomiting and anorexia, later diagnosed as intestinal P. insidiosum [19].  This patient was 
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treated by a subtotal colectomy, followed by administration of the IP.  The patient achieved significant 
improvement by two months post-surgery [19].  In contrast, Mendoza reported two dogs which 
achieved a cure following administration of the IP alone, after prior medical management had failed 
[13]. 
1.1.F.3 Prognosis 
Long-term prognosis in dogs infected with P. insidiosum depends on chronicity of infection, location 
of lesion and treatment modalities used.  In general, the prognosis of chronic infections (> 2 months) is 
poor [13].  Medical management alone is generally thought to have limited efficacy, as P. insidiosum 
does not contain most of the structures targeted by traditional antifungal medications.  For this reason, 
surgical excision is currently considered the mainstay of effective therapy, especially in the dog.  It is 
suspected that only an amputation or radical surgical excision with wide-surgical margins can truly stop 
the spreading of the infection through the subcutaneous planes.  Unfortunately, radical excision is 
difficult in cases where the lesions include the stomach and small intestine or in areas that are not 
surgically resectable, such as the hip or thorax.   
Because of the limited efficacy of these traditional therapies, there has been an interest in the 
development of a product to direct and amplify the patient’s own immunologic response to the 
organism.  One attempt to achieve this has resulted in the development of the previously described IP.  
Unfortunately, valid assessment of this product is complicated due to the paucity of knowledge 
regarding the immune response against P. insidiosum, either with or without administration of the IP.  
While serum concentrations of anti-P. insidiosum IgG have been measured after administration of 
this product in naturally-infected dogs, these measurements have not been performed at any consistent 
time (or in any consistent manner) after administration of the product.  For this reason, it is unknown 
whether administration of this immunotherapy product (IP) can be expected to interfere with serologic-
based monitoring techniques.  Adoption of this technology has been avoided by many veterinary 
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clinicians because of concerns that it might interfere with serologic monitoring using IgG concentrations 
with an ELISA.  
1.1.G Objectives 
The specific objectives of this study are to characterize the IgG antibody responses of healthy dogs 
treated with a purified protein mixture made from Pythium insidiosum, using the manufacturer’s 
suggested protocol, and evaluate IP site reactions.  An additional goal was to obtain serum samples for 
future analysis of cytokine and other antibody isotype levels in serum.  We hypothesize that repeated 
administration of this commercially available immunotherapeutic product will increase IgG 
concentrations over time following each administration of the IP in a population of healthy dogs.  We do 
not expect significant injection site reactions in the dogs in this study. 
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Chapter 2. Quantitation of Anti-Pythium insidiosum Antibodies before and after Immunotherapy 
in Healthy Dogs 
2.1 Introduction 
Pythium insidiosum is an aquatic oomycete that causes invasive, progressive granulomatous lesions 
of the skin in dogs, horses, and cats, and of the gastrointestinal tract in dogs.  Although pythiosis has 
traditionally been observed most often in tropical and subtropical climates, over the past two decades it 
has been recognized in a broader area, including California [1] and Wisconsin [2] in the United States.  
Obtaining a definitive diagnosis may be challenging, as histologic findings are insufficiently unique to 
differentiate pythiosis from lagenidiosis, paralagenidiosis, and zygomycosis.  Methods that have been 
used to confirm a diagnosis include IgG antibody serology [3] and culture followed by molecular 
confirmation of isolate identity by species-specific PCR or ribosomal RNA gene sequencing [4].  In 
addition to being used as a tool for initial diagnosis, IgG antibody serology has also been used to monitor 
response to treatment in dogs, with maintenance of high antibody concentrations post-surgery 
suggesting incomplete excision or early relapse [5].  Conversely, decreasing anti-P. insidiosum IgG 
concentrations have been observed in patients that are cured [6].   
The most effective treatment for pythiosis is wide surgical excision, which is sometimes followed by 
antifungal chemotherapy.  Unfortunately, complete surgical resection is often not possible because of 
lesion location, and the effectiveness of medical therapy alone is limited by the fact that ergosterol is 
not a major component of the oomycete cell membrane.  As a result, alternative modes of therapy have 
been explored, including an immunotherapy product (IP) that was originally developed for and 
evaluated in horses, and which has subsequently been recommended for use in dogs and people.  
Although there is published evidence showing some efficacy in horses, [7, 8] efficacy in dogs has not 
been well evaluated and anecdotally appears to be poor [9].  In addition, although a mechanism of 
action for the product has been proposed, [10] there have been no studies designed to evaluate the 
effect of the IP on the immune response in any species.   
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In addition to a lack of information about the mechanism of action of the IP, information regarding 
its potential effect on post-treatment monitoring of anti-P. insidiosum IgG concentrations is limited.  As 
a result, some clinicians avoid use of immunotherapy because of concerns that it may interfere with 
subsequent serologic monitoring.  Although four individual canine cases have been described in which 
anti-P. insidiosum IgG concentrations were monitored following treatment that included 
immunotherapy, administration protocols (frequency, number, route) and post-IP administration 
sampling intervals varied widely [2, 6, 11, 12].  
Therefore, the goals of this study were to evaluate the effect of IP administration on anti-P. 
insidiosum IgG concentrations in healthy dogs in order to better characterize the effect of IP 
administration on the canine humoral immune response and to provide initial information about the 
potential effect of IP administration on post-treatment serologic monitoring.  
2.2 Materials and methods 
Seven adult, female, purpose bred, intact hound-mixes from the Division of Laboratory Animal 
Medicine (DLAM) colony were enrolled in this study with a median of 7 +/- 2.73 years.  Dogs were 
housed in either single or paired indoor AALAC-International-approved kennels, with controlled 
temperature and climate for the duration of the study.  Temperature and relative humidity (RH) were 
measured using Onset Computer Corporation HOBO (Bourne, MA).  Prior to the beginning of the study, 
all dogs were screened for preexisting health conditions by a thorough physical examination, complete 
blood count (CBC), biochemistry profile and urinalysis.  All procedures described in this experiment were 
approved by the Institutional Animal Care and Use Committee of Louisiana State University School of 
Veterinary Medicine.   
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The IP was obtained from Pan American Veterinary Laboratories (Hutto, TX) and was kept 
refrigerated at 4° C until use.  On days zero, seven and 21, the IP was administered as per 
manufacturer’s instructions (1 mL subcutaneously; Figure one).  Injection sites were rotated so as to not 
inject in the same site more than once (cranial left thorax, cranial right thorax and caudal left thorax).  
All administration sites were shaved and photographed pre- and post-injection to facilitate examination.  
Injection sites were monitored for pruritus, swelling, induration, erythema, erosion, ulceration, necrosis 
and discomfort.  Body temperature was measured twice daily for seven days after every injection.  A 
temperature of 103.5° F or above was considered to be elevated [13].  Full physical examinations were 
performed weekly for the duration of the study. 
 
 
Figure 2.1.  Timeline for the quantitation of anti-Pythium insidiosum IgG concentrations before and after 
immunotherapy in healthy dogs.  Serum was collected every seven days until Day 56 and three 
injections of the immunotherapy product (IP) were administered on Day zero, seven and 21.  Injection 
sites were evaluated after each IP and temperature was collected twice daily for seven days post-
injection. 
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Blood collection (20 mL) via jugular or saphenous venipuncture was performed weekly (D0 until 
D56; Figure one).  Serum was harvested and stored in 200 µL aliquots at -80° C until analyzed.   An ELISA 
previously described for the serodiagnosis of pythiosis in dogs was used to measure anti-P. insidiosum 
IgG concentrations [3].  Briefly, 96-well microtiter plates (Immulon 2HB, Thermo Scientific, Rochester, 
NY) were coated overnight with a soluble mycelial antigen solution prepared from vortexed P. 
insidiosum cultures.  Wells were washed with phosphate-buffered saline-0.05% Tween (PBST), and then 
blocked with bovine serum albumin in PBST (BSA-PBST).  Sera were diluted in PBST (1:2000) and plated 
in quadruplicate wells.  Bound anti-P. insidiosum IgG was detected using a horseradish peroxidase-
conjugated anti-canine IgG (Rockland Antibodies and Assays, Limerick, PA) in BSA-PBST, followed by the 
addition of TMB two-component substrate (SeraCare, Milford, MA).  Absorbance was measured at 450 
nm using a BioTek Plate Reader (Epoch Microplate Spectrophotometer, Winooski, VT).  Results were 
recorded as percent positivity (PP) relative to a strong positive control serum run in quadruplicate on 
each plate, calculated as: 
𝑀𝑒𝑑𝑖𝑎𝑛 𝑜𝑝𝑡𝑖𝑐𝑎𝑙 𝑑𝑒𝑛𝑠𝑖𝑡𝑦 𝑠𝑎𝑚𝑝𝑙𝑒 𝑠𝑒𝑟𝑢𝑚
𝑀𝑒𝑑𝑖𝑎𝑛 𝑜𝑝𝑡𝑖𝑐𝑎𝑙 𝑑𝑒𝑛𝑠𝑖𝑡𝑦 𝑟𝑒𝑓𝑒𝑟𝑒𝑛𝑐𝑒 𝑠𝑒𝑟𝑢𝑚
 𝑥 100% .  A negative control of BSA-PBST 
was included on each plate.  
Anti-P. insidiosum IgG concentrations were evaluated over time in comparison to baseline.  Data 
was checked for normality using a Kolmogorov-Smirnoff Test, and was analyzed using a Repeated 
Measures Analysis of Variance (ANOVA) as a Randomized Block Design (RBD) on the plates.  Animal ID 
was a random effect using Proc Mixed Procedure.  Significance was set at P ≤0.05.  SAS Version 9.4 (SAS 
Institute Inc) was used for data analysis. 
2.3 Results 
Clinically significant adverse effects of the IP (including injection site induration, swelling and 
pruritus) were not observed.  Body temperature remained normal in all dogs at all time points.  
Erythema was noted at 7/21 injection sites, but resolved within seven days of IP administration in all 
instances.  No dog developed erythema at all three injection sites.  Mild crusting was noted in three 
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dogs at either the first or the second injection site on Days 35 to 42, but these lesions resolved by Day 
56 without treatment.  These animals also had mild erythema associated with either site one (cranial left 
thorax) or site two (cranial right thorax) during the study.  By day 56, injection sites were normal in all 
dogs.   
Anti-P. insidiosum IgG concentrations remained within the previously-described reference interval 
during all time points of this study (Table 1, Figure 2), and no significant change in PP was observed over 
time (p = 0.2814; Figure 3, Table 1).  
Overall, the PP demonstrated by the dogs was highly variable, and significant differences were 
observed between all of the dogs at all time-points (including at baseline; Figure 2).  One of the seven 
dogs started with considerably higher baseline anti-P. insidiosum concentrations relative to the other six 
dogs (Dog D, Figure 2, Baseline PP = 13.35%) and remained at this level throughout the study.  When this 
individual was removed from the model, the overall increase in PP was still not significant (p = 0.1157, 
Table 1).   
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Figure 2.2 Anti-P. insidiosum IgG concentrations reported as percent positivity (PP) in individual dogs 
before and after immunotherapy.  
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Figure 2.3: Median, quartiles and ranges of IgG PP (percent positivity) across time for anti-Pythium 
insidiosum antibodies before and after immunotherapy product (IP). 
 
 
 
 
 
 
Table 1: Averages, standard deviation and standard error for IgG PP (percent positivity) across time for 
anti-P. insidiosum antibodies before and after immunotherapy product. 
 
 Anti-P. insidiosum PP Data 
p > 0.2814 
PP Data Excluding Dog 4 
p > 0.1157 
Days Mean Standard 
Deviation 
Standard 
Error 
Mean Standard 
Deviation 
Standard 
Error 
0 7.457 3.023 1.142 3.874 3.241 1.871 
7 7.374 0.889 0.336 2.866 3.913 2.259 
14 8.911 1.995 0.754 3.887 4.395 2.537 
21 8.514 1.272 0.480 3.422 4.427 2.556 
28 8.797 1.601 0.605 3.667 4.469 2.580 
35 9.234 2.525 0.954 4.238 4.397 2.538 
42 9.177 2.152 0.813 4.047 4.492 2.593 
49 8.448 1.552 0.586 3.529 4.287 2.475 
56 8.32 0.955 0.361 3.212 4.433 2.559 
 
 
 
22 
 
2.4 Discussion 
Immunotherapy in the form of various P. insidiosum antigen extracts has been used for almost 40 
years for the treatment of horses with pythiosis [14].  More recently, a commercially-available product 
has been marketed for the treatment of P. insidiosum infections in horses and dogs.  This product is a 
combination of P. insidiosum hyphal and secreted antigens.  There are several manuscripts suggesting 
that this immunotherapy has some efficacy against P. insidiosum infections in horses and humans [7].   
The response to immunotherapy has been studied most thoroughly in the horse.  In 2003, Mendoza 
reported resolution of pythiosis in 13 out of 18 horses using the IP evaluated in the current study [8].  
These horses had previously failed to respond to topical medications or by surgical excision.  A second 
manuscript by Mendoza claimed that approximately 60% of 600 horses had been successfully treated by 
immunotherapy, but specific details were not provided [10].   
Immunotherapy has also been used with some success in humans.  Administration of 
immunotherapy was associated with clinical cure in one 14-year old boy with vascular pythiosis who had 
previously failed to respond to antifungal or surgical therapy [15].  A subsequent case series 
demonstrated that four out of eight humans treated with the IP were “without clinical or radiographic 
signs of disease, i.e. arterial occlusion for about 24-30 months of follow-up” [16], while two patients 
showed a partial response.  All of these patients had previously failed to respond to medical and/or 
surgical therapy.  A later case series report described treatment success rates of 55.5% and 44.4% for 
vascular and ocular pythiosis, respectively [17].  However, these patients also received systemic 
(itraconazole and terbinafine, +/- voriconazole, ketoconazole or posaconazole) antifungal therapy.  
Furthermore, all of the vascular pythiosis cases had also been treated by radical surgical excision, with 
clinical cure observed only in patients in which clean surgical margins had been obtained. 
In contrast, while there have been a small number of manuscripts demonstrating a good clinical 
outcome in canine patients receiving the IP (in conjunction with other therapy), anecdotally the clinical 
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efficacy of this product in this species appears to be poor [2, 6, 8, 11, 12, 18].  Of the 12 published 
reports in which immunotherapy was used for the treatment of canine pythiosis, only five had a 
favorable outcome.  In one case series by Mendoza, immunotherapy alone was used to treat six dogs 
which had previously failed to respond to surgery or antibiotic or antifungal therapy [8].  Two of these 
dogs (one with intestinal involvement and one with cutaneous involvement) demonstrated clinical 
resolution of the disease.  Clinical resolution was also reported in one mixed breed dog with intestinal 
pythiosis (which had also been treated by subtotal colectomy as well as a combination of itraconazole 
and terbinafine); in one beagle with intestinal pythiosis (which had also received a combination of 
itraconazole and terbinafine) and one dog with cutaneous pythiosis [6, 11, 12].  The remaining cases (all 
with cutaneous disease) failed to demonstrate clinical improvement following immunotherapy 
administration [2, 18]. 
The development of an effective immunotherapeutic product should ideally be based upon a 
thorough understanding of the immunologic response to the organism in question.  Although it is 
beyond the scope of this manuscript to provide a detailed summary of the current knowledge of 
antifungal immunity, it is possible to include a brief discussion of some of the key features.  Effective 
antifungal immunity is dependent upon a complex interaction between cells and elements of the innate 
and adaptive immune systems.  For most fungi, the development of a Th1 immune response appears to 
be the most critical for effective elimination of the pathogen [19-21].  These responses are characterized 
by a robust cell-mediated response, in which phagocytes (especially macrophages) become strongly 
activated, increasing their rate of phagocytosis and their ability to kill phagocytized organisms [19, 21].  
Other cells may also participate in the cell mediated response, including natural killer cells, which may 
induce apoptosis and elimination of infected cells, and which may possibly be able to directly damage 
extracellular fungi [22].  Th17 immune responses may also play a role in antifungal defense.  These are 
characterized by the recruitment and activation of neutrophils, which can both phagocytize and kill 
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small fungal elements directly as well as damage or inhibit larger fungal elements via the elaboration of 
neutrophil extracellular traps [21, 22].  While the critical role of Th1 and Th17 effector elements is well 
established for most fungal infections, the relevance of Th2-mediated anti-fungal antibody responses 
appears to be more variable and less certain.  Although antibodies do appear to play a significant role in 
the defense against certain organisms (namely Aspergillus), their role in effective defense against other 
organisms (such as Candida) is less certain and may even be counterproductive [19]. 
In contrast to many true fungal pathogens (such as Candida and Aspergillus), there is a paucity 
of knowledge regarding the immunologic processes associated with either the development of pythiosis 
or with its resolution.  In dogs and horses, infection with P. insidiosum has been associated with 
development of anti-P. insidiosum IgG antibodies, and resolution of infection is typically associated with 
a decrease in antibody concentrations [3, 23, 24].  However, it is unknown what role (if any) these 
antibodies play in clearance of infection.   
Clinical pythiosis is frequently referred to as a Th2 “polarized” immune response, while 
successful treatment of P. insidiosum infections is commonly attributed to a Th1 immune response.  
Although these statements are frequently repeated in the literature, there are no published data 
regarding the response of immune cells or secreted factors to infection with P. insidiosum, and it may or 
may not be valid to extend assumptions based upon knowledge of antifungal immune responses to this 
non-fungal organism.  Evidence cited in support of this assertion includes the observation that histologic 
lesions induced by P. insidiosum are generally characterized by eosinophilic inflammation, while 
resolving lesions typically contain fewer eosinophils and larger numbers of macrophages and 
lymphocytes.  There is a single published report of a human patient demonstrating a relative decrease in 
serum P. insidiosum-specific IgE as well as interleukins 4 (IL-4) and IL-5, and a relative increase in IL-2 
after successful therapy [16].  However, no similar studies have been performed in non-human species. 
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While it is true that these observations might be consistent with a switch from a Th2 to a Th1-polarized 
immune response, this evidence is far from definitive. 
In the current study, administration of the IP to healthy dogs was not associated with a significant 
change in anti-P. insidiosum IgG concentrations.  One potential explanation is that the IP may simply fails 
to induce a productive, effective immune response in this species.  This idea would be supported by 
clinical observations that the IP is fairly ineffective for the treatment of pythiosis in dogs.  Given the 
relatively higher clinical response rate to the IP in horses and humans in comparison to dogs it would be 
interesting to determine whether there are significant IgG responses to IP administration in these 
species.  Another, perhaps more likely, explanation would be that the IP generates a predominantly cell-
mediated rather than humoral response.   
The current work does have some limitations.  The first involves the relatively small sample size.  In 
general, anti-P. insidiosum IgG concentrations (both pre- and post-IP administration) demonstrated 
significant variability between individuals, although still remaining within the reference interval for 
healthy dogs.   
Perhaps a more significant limitation was that this study was performed on healthy dogs with no 
known exposure to P. insidiosum.  While this selection was necessary to determine the expected 
antibody response to the IP under controlled conditions, our results might not necessarily reflect the 
results seen in naturally infected dogs.  It is possible that natural infection would produce enough 
immunologic “priming” that subsequent challenge with the IP would be associated with a significant rise 
in anti-P. insidiosum IgG concentrations.  Further investigation would require administration of the IP to 
infected animals.  However, under these circumstances, it may be difficult to determine the relative 
impact of the IP versus that of the infection itself.   
In conclusion, this study demonstrated that administration of a commercially-available P. insidiosum 
immunotherapeutic product does not produce a significant increase in anti-P. insidiosum IgG 
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concentrations when administered to healthy dogs using the protocol suggested by the manufacturers.  
These results may suggest a failure of the product to induce a productive immune response in this 
species, or might indicate that factors other than IgG are responsible for the resolution of P. insidiosum 
infections in the dog.  Regardless, the lack of impact on serum anti-P. insidiosum IgG levels suggests that 
administration of the IP would not be expected to interfere with subsequent serologic monitoring in 
affected dogs.  However, further evaluation of the antibody responses to this product in naturally 
affected dogs will be required before a firm conclusion can be prudently drawn.   
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Chapter 3. Conclusions 
Pythium insidiosum is an aquatic oomycete found in tropical, subtropical and some temperate 
climates worldwide, especially in the Gulf Coast States [1].  Pythiosis is characterized by severe, 
progressive cutaneous or gastrointestinal disease [1] in dogs, horses and sometimes humans.  
Treatment for this infection typically consists of surgical intervention combined with prolonged 
antifungal treatment.  Unfortunately, traditional antifungal medications have limited efficacy due to the 
lack of ergosterol and chitin in P. insidiosum’s cellular wall, as the organism is more closely related to 
algae than to fungi.  
Recently, and immunotherapeutic product (IP) has been developed for use in horses, dogs and 
humans.  The IP evaluated in this study is a modification of Miller’s immunotherapy [2] and contains 
both cytoplasmic antigens and secreted exoantigens from P. insidiosum [3].  Although this product 
appears to be efficacious in horses and in some humans, anecdotally the response in dogs has been 
poor.  Evaluation of the efficacy of this product has been limited by several factors, including a lack of 
information regarding its mechanism of action.  In addition, many veterinarians have been hesitant to 
use this product, as it is unknown whether administration of the IP affects anti-P. insidiosum IgG 
antibody concentrations, which are commonly used to monitor the efficacy of treatment [4].  
In this study, administration of the IP did not induce significant changes in anti-P. insidiosum IgG 
antibody concentrations, nor were significant injection site reactions observed in the dogs used in this 
study.  The lack of a response in IgG antibody concentrations might suggest that administration of this 
product does not induce the development of a productive immune response in the dog.  Alternately, the 
product might be more effective at producing a cell-mediated response rather than a humoral response.  
Investigation of this hypothesis might include the determination of whether an IgG response is 
generated after administration of this product to horses, in which the clinical response to this product is 
better documented. 
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Future studies include the characterization of the IgG antibody responses in healthy horses as well 
as determination of the responses of other antibody isotypes such as IgE.  Another area of future 
research would include determination of serum cytokine profiles after administration of this product, as 
well as in naturally infected animals at different stages of infection.  There is a single report of a human 
patient demonstrating a relative decrease in anti-P. insidiosum serum IgE concentrations as well as IL-4 
and IL-5, and a relative increase in IL-2 after successful therapy [5].   
In conclusion, this study demonstrated that administration of a commercially-available P. insidiosum 
immunotherapy product does not produce a significant increase in anti-P. insidiosum IgG concentrations 
when administered to healthy dogs using the protocol suggested by the manufacturers.  These results 
suggest that administration of the IP would not interfere with subsequent serological monitoring in 
affected dogs.  However, further evaluation of the antibody responses to this product in naturally 
infected dogs will be required before a firm conclusion can be prudently drawn.   
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